Beyond the Implant: A New Study Seeks to Build Trust in Chronic Pain Relief

TAMPA, FL – June 09, 2026 – For the millions who live with the grinding reality of chronic lower back pain, the search for relief is a journey often marked by frustration and temporary fixes. It’s a silent epidemic that chips away at daily life, and for a significant number—up to 30 percent—the source is not the spine itself, but a frequently overlooked pair of joints deep in the pelvis: the sacroiliac, or SI, joints.

In a landscape crowded with medical innovations promising quick fixes, one company is taking a deliberately slower, more rigorous path. Today, PainTEQ, a Florida-based medical technology firm, announced the start of a major clinical trial for its new SI joint fusion device. The move signals a deeper strategy, one that bets on the power of evidence to build the most valuable commodity in healthcare: trust. The TRAQTION Study, as it's called, isn't just about evaluating a new piece of hardware; it’s an inquiry into what it takes to create lasting value for patients, physicians, and the healthcare system itself.

The Hidden Cause of Chronic Pain

The sacroiliac joints act as the critical junction between the spine and the pelvis, transferring the weight of the upper body to the legs. When they become dysfunctional, whether through injury, arthritis, or the stresses of pregnancy, the resulting pain can be severe and debilitating. Yet for decades, SI joint pain was often misdiagnosed as a generic lumbar spine issue, leading patients down a path of ineffective treatments.

Today, awareness has grown, and so have the treatment options. The journey typically begins with conservative care: physical therapy, anti-inflammatory medications, and therapeutic injections. While helpful, these methods often provide only temporary relief. For those with persistent, severe pain, the next step has increasingly become minimally invasive SI joint fusion—a procedure to permanently stabilize the joint. This approach has shown remarkable success, with studies indicating that over 80 percent of patients experience significant and lasting pain relief.

This is the world PainTEQ operates in. The company has helped pioneer the posterior approach to SI joint fusion, and its latest technology, the TRAQ™ allograft, aims to refine the procedure even further. But in a competitive market, a new device is not enough. The real challenge is proving its long-term worth.

Engineering Stability, Building on Biology

At its core, the TRAQ™ system is an allograft—a precisely shaped piece of donor bone—designed for minimally invasive implantation. What sets it apart is its engineering. The device features unique triangular piercing barbs designed to achieve what the company calls “bi-cortical fixation.” In simpler terms, it’s designed to anchor into the hard, outer layers of bone on both sides of the joint—the sacrum and the ilium. This approach, according to one of the company's lead engineers, was an intentional choice to create the robust stabilization the joint requires.

Delivered through a small, one-inch incision, the implant is designed to minimize tissue disruption while providing a strong mechanical lock. It also incorporates a window filled with bone graft material, positioned to encourage the patient's own bone to grow across the joint, creating a permanent, biological fusion. This combination of immediate mechanical stability and long-term biological integration represents a thoughtful evolution in posterior SI joint treatment.

“The enrollment of the first patient in the TRAQTION Study represents an important milestone in the continued evolution of posterior sacroiliac joint procedures,” noted Eric Cornidez, M.D., M.B.A., Chief Medical Officer at the Pain Institute of Southern Arizona, one of the participating study sites. “I am pleased to participate in this study and contribute to the growing body of evidence evaluating this cortical-piercing posterior approach.”

In Evidence We Trust: The Rigor of the TRAQTION Study

This is where PainTEQ’s strategy pivots from pure engineering to the science of trust. Instead of relying solely on laboratory data and early surgical experience, the company has launched the TRAQTION Study, a prospective, multicenter clinical trial that will follow up to 100 patients across ten U.S. sites for two full years.

This study design is the gold standard for generating high-quality clinical evidence. “Prospective” means it’s designed to collect data as it happens, not by looking backward at old records. “Multicenter” ensures the results aren’t skewed by the unique skills of a single surgeon or the demographics of a single location. And the 24-month follow-up is critical for proving durability—demonstrating that the relief patients experience isn't just a short-term effect.

Lalit Venkatesan, Senior Vice President of Clinical Research at PainTEQ, articulated the philosophy behind the trial. “The cortical engagement approach represents a meaningful step forward for PainTEQ, and TRAQTION is built to evaluate it with the prospective rigor the field deserves,” he stated. “Two years of follow-up across a multicenter cohort will give us a clear view of durability, safety, and patient experience. This is exactly the evidence physicians need to inform how they position this procedure for their patients.”

In an industry where marketing can sometimes outpace science, this commitment to generating robust, long-term data is a powerful statement. It's a recognition that to truly serve patients and earn the confidence of physicians, a company must be willing to put its technology to the test in the most transparent way possible.

From Patient Outcomes to Public Policy

The implications of the TRAQTION Study extend far beyond this single device. A key component of the trial is the collection of data on “healthcare utilization.” This means researchers will track not just pain scores, but also the full spectrum of a patient’s interaction with the healthcare system post-procedure, including follow-up appointments, additional treatments, and overall costs. This data is invaluable for healthcare economists, insurers, and policymakers.

In a system grappling with rising costs, proving that a medical device is not only clinically effective but also cost-effective can transform its adoption. Positive data on healthcare utilization could pave the way for more favorable insurance coverage, making the technology accessible to more patients. It can also influence the development of clinical guidelines that shape how thousands of physicians decide to treat SI joint pain.

The minimally invasive SI joint fusion market is a dynamic and growing space, projected to exceed $2 billion globally within the next decade. While PainTEQ faces formidable competition from industry giants like SI-BONE and Medtronic, its strategy of investing heavily in clinical evidence could be its key differentiator. By building a foundation of trust through rigorous science, the company is positioning itself not just as a vendor of implants, but as a partner in advancing the standard of care for one of modern medicine’s most persistent and personal challenges.